[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 4 of about 4
1. Giagounidis AA, Hildebrandt B, Heinsch M, Germing U, Aivado M, Aul C: Acute basophilic leukemia. Eur J Haematol; 2001 Aug;67(2):72-6
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute basophilic leukemia.
  • Acute basophilic leukemia has recently been included into a revised classification of acute leukemias proposed by the WHO panel.
  • Due to the rarity of the disease, consistent diagnostic criteria are lacking.
  • We report on two cases of acute basophilic leukemia that occurred in our department during the last 10 yr.
  • Treatment of our patients consisted of supportive treatment in the one with normal karyotype and aggressive chemotherapy in the other patient.
  • Both patients died within one year after diagnosis due to progressive or recurrent leukemia.
  • [MeSH-major] Leukemia, Basophilic, Acute / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Chromosome Aberrations. Coloring Agents. Cytarabine / administration & dosage. Cytoplasmic Granules / chemistry. Fatal Outcome. Humans. Idarubicin / administration & dosage. Immunophenotyping. Karyotyping. Leukocyte Count. Male. Middle Aged. Neoplasm Proteins / analysis. Neoplastic Stem Cells / chemistry. Neoplastic Stem Cells / pathology. Periodic Acid-Schiff Reaction. Peroxidase / analysis. Recurrence. Tolonium Chloride. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11722593.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Neoplasm Proteins; 04079A1RDZ / Cytarabine; 15XUH0X66N / Tolonium Chloride; EC 1.11.1.7 / Peroxidase; ZRP63D75JW / Idarubicin
  •  go-up   go-down


2. Yokohama A, Tsukamoto N, Hatsumi N, Suto M, Akiba T, Uchiumi H, Maehara T, Matsushima T, Karasawa M, Murakami H, Shinonome S, Saito H, Nojima Y: Acute basophilic leukemia lacking basophil-specific antigens: the importance of cytokine receptor expression in differential diagnosis. Int J Hematol; 2002 Apr;75(3):309-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute basophilic leukemia lacking basophil-specific antigens: the importance of cytokine receptor expression in differential diagnosis.
  • De novo acute basophilic leukemia (ABL) is a rare form of myeloid leukemia.
  • The low prevalence of ABL makes it difficult to define its clinical characteristics and to establish an effective therapeutic protocol.
  • The diagnosis of ABL depended on the following:.
  • The patient achieved complete remission with intensive chemotherapy composed of idarubicin and cytosine arabinoside and was disease free during the following 30 months.
  • [MeSH-major] Antigens, CD / blood. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Basophilic, Acute / diagnosis. Mast Cells / immunology. Receptors, Cytokine / genetics
  • [MeSH-minor] Bone Marrow / pathology. Cytarabine / administration & dosage. Diagnosis, Differential. Humans. Idarubicin / administration & dosage. Male. Middle Aged. Receptors, IgE / blood

  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 2000 Feb;32(1):52-5 [10740808.001]
  • [Cites] Exp Hematol. 1993 Jan;21(1):119-25 [7678084.001]
  • [Cites] J Allergy Clin Immunol. 1994 Dec;94(6 Pt 2):1177-83 [7798557.001]
  • [Cites] Br J Haematol. 1997 Jul;98(1):170-6 [9233581.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Apr;85(7):2288-92 [3258425.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):735-9 [7678463.001]
  • [Cites] Cytometry. 1999 Mar 1;35(3):249-59 [10082306.001]
  • [Cites] Blood. 1989 Aug 1;74(2):613-21 [2665851.001]
  • [Cites] Am J Hematol. 1989 Jul;31(3):173-80 [2787115.001]
  • [Cites] Blood. 1990 Nov 15;76(10):1956-61 [1700728.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Oct 15;84(2):99-104 [8536230.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2333-42 [10498605.001]
  • [Cites] Eur J Clin Invest. 1995 Oct;25(10):715-20 [8557056.001]
  • [Cites] Blood. 1989 May 1;73(6):1504-12 [2653458.001]
  • [Cites] Blood. 1989 Aug 1;74(2):565-71 [2546627.001]
  • [Cites] Blood. 1999 May 15;93(10):3338-46 [10233886.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Blood. 1992 Dec 15;80(12):3009-21 [1281684.001]
  • [Cites] Neoplasma. 1998;45(4):198-203 [9890661.001]
  • [Cites] Blood. 1982 Jul;60(1):38-45 [7082845.001]
  • [Cites] Immunology. 1996 Apr;87(4):535-43 [8675206.001]
  • [Cites] Br J Haematol. 1995 Mar;89(3):650-2 [7734371.001]
  • [Cites] Leuk Lymphoma. 1999 Jan;32(3-4):269-78 [10037024.001]
  • [Cites] Leuk Lymphoma. 1995;18 Suppl 1:57-60 [7496356.001]
  • [Cites] Blood. 1992 Nov 1;80(9):2237-45 [1384799.001]
  • [Cites] Am J Clin Pathol. 1991 Aug;96(2):160-70 [1862771.001]
  • [Cites] Adv Immunol. 1992;52:333-423 [1332448.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1987 Spring;9(1):27-32 [2438957.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2343-56 [10498606.001]
  • [Cites] Cancer. 1995 Jan 1;75(1):110-4 [7804964.001]
  • [Cites] J Allergy Clin Immunol. 2000 Dec;106(6):1190-5 [11112905.001]
  • [Cites] J Med. 1995;26(5-6):235-40 [8721900.001]
  • [Cites] J Allergy Clin Immunol. 2000 Aug;106(2):321-8 [10932077.001]
  • (PMID = 11999362.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Receptors, Cytokine; 0 / Receptors, IgE; 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


3. Scolyer RA, Brun M, D'Rozario J, Webb M: Acute basophilic leukemia presenting with abnormal liver function tests and the absence of blast cells in the peripheral blood. Pathology; 2000 Feb;32(1):52-5
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute basophilic leukemia presenting with abnormal liver function tests and the absence of blast cells in the peripheral blood.
  • Acute basophilic leukemia is an uncommon form of acute leukemia, rarely occurring as a de novo disease.
  • We describe a case of de novo acute basophilic leukemia occurring in a 47-year-old man who presented with abnormal liver function tests in the absence of leukemic infiltration of the liver.
  • We postulate that this presentation occurred as a consequence of pathophysiological features of the malignant basophilic blast cells.
  • [MeSH-major] Leukemia, Basophilic, Acute / diagnosis. Leukemic Infiltration / pathology. Liver / pathology. Liver Function Tests. Neoplastic Stem Cells / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Cells / pathology. Cytarabine / therapeutic use. Cytoplasmic Granules / ultrastructure. Diagnosis, Differential. Drug Therapy, Combination. Fatal Outcome. Humans. Idarubicin / therapeutic use. Immunophenotyping. Karyotyping. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Function Tests.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10740808.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


Advertisement
4. Moser AM, Manor E, Narkis G, Kapelushnik J: Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up. Cancer Genet Cytogenet; 2006 Oct 1;170(1):54-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.
  • The case of an 11-year-old child with adult-type chronic myeloid leukemia, Philadelphia (BCR-ABL) positive, reverse transcription-polymerase chain reaction negative for the major, minor, and micro breakpoints is presented.
  • In the course of 3 years, the child failed to respond to treatment with hydroxyurea, refused all therapy for 6 months, was intolerant to alpha-interferon and progressed, while on imatinib, to acute basophilic leukemia.
  • A secondary cytogenetic clonal evolution, i(17q), developed during hydroxyurea treatment and a tertiary clonal evolution, +8, was detected during imatinib treatment.
  • It is not clear to what extent the several factors (undefined BCR-ABL breakpoint, treatment avoidance, and initial treatment choices, alone or in combination) played a role in the imatinib relapse and resistance and in the disease progression.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Genes, abl. Leukemia, Basophilic, Acute / surgery. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Benzamides. Bone Marrow Transplantation. Child. Disease Progression. Drug Resistance, Neoplasm. Humans. Imatinib Mesylate. Immunophenotyping. In Situ Hybridization, Fluorescence. Male. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965955.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down






Advertisement